Alejandra Lorenzen to Present Huang Lab Research at the AIM 2026 Health R&D Summit

SAN ANTONIO, Texas — The Huang Lab at the Mays Cancer Center at UT Health San Antonio announces that Alejandra Lorenzen, PhD student in the lab, will present at the AIM 2026 Health R&D Summit on May 19, 2026. Her presentation features the lab's work on a synthetic blood oxygen carrier, OcVe. We are proud of Alejandra for being chosen to present this work.

The project addresses the long-standing challenge of carrying and delivering oxygen without relying on donated blood. A synthetic oxygen carrier could support trauma care, surgery, and other settings where blood supply is limited. The work reflects the lab's broader interest in metabolism, oxygen biology, and translational technologies with clinical reach.

Abioremedi executive Han Li and members of the Huang Lab will attend the summit to meet potential partners and discuss collaboration around the OcVe program. The summit offers a venue to connect the science with the partners and resources needed to advance it.

"Alejandra is driving an ambitious project at the intersection of chemistry, physiology, and unmet clinical need," said Dr. Gang Huang, principal investigator. "We are proud to see her chosen for this presentation and glad to share the work with the R&D community at AIM."

About the Huang Lab

The Huang Lab at UT Health San Antonio is a basic and translational cancer research group within the MD Anderson Mays Cancer Center at UT Health San Antonio. Our team integrates hematology and solid tumor biology with immunology and metabolism to uncover mechanisms and design interventions. We advance cell and biologic therapies, including CAR T-cell approaches for solid tumors. We also conduct research in trauma and military health. We move discoveries toward clinical impact through product development and collaborations with clinicians and industry. Education and mentorship are core to our mission. We train students, postdoctoral fellows, and early-career scientists in rigorous, multidisciplinary research. Together, we aim to deliver therapies and technologies that improve patient outcomes.